| NCT ID | NCT07022041 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Calabria |
| Condition | Sepsis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-07-15 |
| Primary Completion | 2026-07-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-07-15 with a primary completion date of 2026-07-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Sepsis is one of the leading causes of hospital mortality, with a rate of approximately 20% (World Health Organization) among vulnerable patients admitted to high-intensity care units such as CCUs and inpatient wards. Currently, diagnostic criteria such as the Systemic Inflammatory Response Syndrome (SIRS) and the Sequential Organ Failure Assessment (SOFA) score, although widely used, lack sufficient specificity and accuracy. No established parameters are available for early and timely diagnosis. This study aims to address this gap by investigating the variability of blood plasma conductivity and dielectric constant using microwave probes previously validated for non-invasive glucose monitoring. The acquired data will be analyzed using the Anritsu VectorStar VNA to identify innovative and reliable parameters associated with the presence of severe infections.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Cardiology patients without documented infection (Control Group) * Patients with sepsis * Patients with nosocomial infection * Patients with myocarditis, endocarditis, or pericarditis * Ability to provide written informed consent Exclusion Criteria: * Patients with severe or chronic medical conditions that may interfere with study results, such as autoimmune diseases, renal or hepatic failure * Patients taking medications that could affect the measured biophysical parameters, such as corticosteroids or immunosuppressants * Patients with cancer * Patients with diseases involving the immune system (e.g., lymphomas, leukemias) * Patients with congenital or acquired immunodeficiencies (e.g., HIV) * Patients who are unable to read and sign the informed consent form
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07022041 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07022041 currently recruiting?
Yes, NCT07022041 is actively recruiting participants. Contact the research team at antonio.curcio.cardio@unical.it for enrollment information.
Where is the NCT07022041 trial being conducted?
This trial is being conducted at Cosenza, Italy.
Who is sponsoring the NCT07022041 clinical trial?
NCT07022041 is sponsored by University of Calabria. The trial plans to enroll 100 participants.